Chimeric Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Chimeric Therapeutics has a total shareholder equity of A$2.5M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$15.3M and A$12.8M respectively.
Key information
0%
Debt to equity ratio
AU$0
Debt
| Interest coverage ratio | n/a |
| Cash | AU$3.05m |
| Equity | AU$2.47m |
| Total liabilities | AU$12.80m |
| Total assets | AU$15.27m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: CHM's short term assets (A$3.2M) do not cover its short term liabilities (A$10.1M).
Long Term Liabilities: CHM's short term assets (A$3.2M) exceed its long term liabilities (A$2.7M).
Debt to Equity History and Analysis
Debt Level: CHM is debt free.
Reducing Debt: CHM had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CHM has sufficient cash runway for 5 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: CHM is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.